Berlin

• A study to test how well different doses of BI 3034701 are tolerated by healthy men and people with overweight or obesity Ended
  2023-508767-79-00 1 2024-05-15 Healthy volunteer trial
• CSL312_3003 Safety and Pharmacokinetic study in Subjects 2 to 11 Years of Age with Hereditary Angioedema Ended
  2022-502386-13-00 5 2024-05-10 Hereditary angioedema (HAE)
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject … Ended
  2023-505842-24-00 5 2024-05-07 Moderate to Severe Plaque Psoriasis
• A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure … Ended
  2023-507640-36-00 5 2024-04-29 Resistant hypertension (rHTN) defined as blood pressure that remains h
• A Phase I, Randomized, Partial Double-blind, Single dose, 3-Way Cross-over Study to Assess the Lung Exposure Bioequivalence of Budesonide, G … Ended
  2023-509914-12-00 2 2024-04-29 Not applicable, healthy volunteers
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)
• A Study of Nicotine Freshmint Mouthspray in E-cigarette Users Willing to Quit Ended
  2023-505036-35-00 5 2024-04-23 Vaping cessation in e-cigarette users
• Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-res … Ended
  2023-503256-27-00 3 2024-04-18 patients with cystic fibrosis suffering from pancreatic exocrine insuf
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Ended
  2023-510127-30-00 1 2024-04-17 Relapsing Remitting Multiple Sclerosis (RRMS)
• A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity Ended
  2023-506233-30-01 3 2024-04-15 Obesity
• A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended
  2023-507217-10-00 5 2024-04-12 Thyroid eye disease
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended
  2023-503693-20-01 5 2024-04-10 Severe eosinophilic asthma
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• A placebo-controlled safety and tolerability study of intravenous (IV) and subcutaneous (SC) AZD1163 in healthy volunteers Ended
  2023-509574-34-00 1 2024-04-10 Rheumatoid Arthritis
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi … Ended
  2022-501421-20-00 5 2024-04-09 Gout with hyperuricemia
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to … Ended
  2023-504564-42-00 4 2024-04-08 Moderate to Severe Rheumatoid Arthritis
• HIV: Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Ended
  2023-505900-53-00 4 2024-04-08 HIV infection
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis Ended
  2023-505841-22-00 5 2024-04-04 Moderate to Severe Plaque Psoriasis
• A trial to learn about a study drug (STAR-0215) in adults with hereditary angioedema Ended
  2022-502953-32-01 9 2024-04-02 Hereditary Angioedema (HAE)
• A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended
  2023-505022-34-00 4 2024-03-27 Neoplasm malignant
• A research study Looking into blood levels of the medicine NNC0519-0130 in the body of participants with normal or reduced kidney function Ended
  2023-506381-32-00 1 2024-03-25 Type 2 Diabetes Mellitus
• A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab via Subcutaneous Administration in Healthy Vol … Ended
  2023-508041-40-00 3 2024-03-19 healthy volunteers
• A trial to learn how much budesonide, glycopyrronium, and formoterol fumarate (BGF) gets into and moves throughout the body when it is taken … Ended
  2023-504089-43-00 3 2024-03-14 Not applicable, healthy volunteers

Showing 1,417–1,440 of 1,776 trials